10569 studies found for:    NCI
Show Display Options
Rank Status Study
1 Active, not recruiting Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
Conditions: Recurrent Uterine Sarcoma;   Uterine Carcinosarcoma
Interventions: Drug: ixabepilone;   Other: laboratory biomarker analysis
2 Completed Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone;   Drug: pamidronate disodium;   Drug: thalidomide;   Drug: zoledronic acid
3 Completed Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer
Conditions: Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer
Interventions: Drug: bromodeoxyuridine;   Procedure: conventional surgery;   Other: laboratory biomarker analysis
4 Completed Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: alvocidib;   Drug: docetaxel
5 Active, not recruiting
Has Results
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
Conditions: Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer
Interventions: Biological: sargramostim;   Biological: recombinant vaccinia-TRICOM vaccine;   Biological: fowlpox-PSA-TRICOM vaccine;   Drug: bicalutamide;   Drug: goserelin acetate
6 Completed
Has Results
PXD101 in Treating Patients With Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Recurrent Adult Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: belinostat;   Other: laboratory biomarker analysis
7 Terminated Entinostat and Anastrozole in Treating Postmenopausal Women With Triple-Negative Breast Cancer That Can Be Removed by Surgery
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: entinostat;   Drug: anastrozole;   Other: diagnostic laboratory biomarker analysis;   Procedure: therapeutic conventional surgery
8 Active, not recruiting Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer
Conditions: Adult Solid Neoplasm;   Peritoneal Carcinomatosis;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Veliparib
9 Completed Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Recurrent Gastric Cancer;   Stage IIIB Gastric Cancer;   Stage IIIC Gastric Cancer;   Stage IV Gastric Cancer
Interventions: Drug: bortezomib;   Drug: irinotecan hydrochloride;   Other: laboratory biomarker analysis
10 Terminated Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Central Nervous System Germ Cell Tumor;   Adult Choroid Plexus Tumor;   Adult Craniopharyngioma;   Adult Diffuse Astrocytoma;   Adult Ependymoblastoma;   Adult Ependymoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Grade I Meningioma;   Adult Grade II Meningioma;   Adult Grade III Meningioma;   Adult Medulloblastoma;   Adult Meningeal Hemangiopericytoma;   Adult Mixed Glioma;   Adult Myxopapillary Ependymoma;   Adult Oligodendroglioma;   Adult Pilocytic Astrocytoma;   Adult Pineoblastoma;   Adult Pineocytoma;   Adult Subependymoma;   Adult Supratentorial Primitive Neuroectodermal Tumor (PNET);   Meningeal Melanocytoma
Interventions: Drug: EF5;   Procedure: conventional surgery;   Procedure: positron emission tomography;   Radiation: fluorine F 18 EF5;   Other: pharmacological study
11 Completed Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia
Condition: Leukemia
Intervention: Biological: monoclonal antibody Mik-beta-1
12 Completed Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer
Condition: Recurrent Ovarian Epithelial Cancer
Interventions: Biological: ALVAC-hB7.1;   Biological: recombinant interferon gamma;   Other: laboratory biomarker analysis
13 Unknown  Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
Conditions: Liver and Intrahepatic Biliary Tract Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: selumetinib;   Other: laboratory biomarker analysis
14 Recruiting WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Conditions: Childhood Solid Neoplasm;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Neuroblastoma
Interventions: Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: WEE1 Inhibitor MK-1775
15 Completed Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
Conditions: Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma;   Stage IA Malignant Mesothelioma;   Stage IB Malignant Mesothelioma;   Stage II Malignant Mesothelioma;   Stage III Malignant Mesothelioma;   Stage IV Malignant Mesothelioma
Interventions: Drug: sorafenib tosylate;   Other: laboratory biomarker analysis
16 Active, not recruiting Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer
Conditions: Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Biological: Bevacizumab;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis
17 Completed 3-AP in Treating Patients With Advanced or Metastatic Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: triapine;   Other: pharmacological study;   Procedure: laboratory biomarker analysis
18 Completed Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IB Non-small Cell Lung Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Procedure: therapeutic conventional surgery
19 Completed
Has Results
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Recurrent Gastric Cancer;   Stage IIIA Gastric Cancer;   Stage IIIB Gastric Cancer;   Stage IIIC Gastric Cancer;   Stage IV Gastric Cancer
Interventions: Drug: alvocidib;   Drug: irinotecan hydrochloride;   Other: laboratory biomarker analysis
20 Completed Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Intervention: Drug: irofulven

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years